Mobile website
Clinical Research
Preparation of PHA-CD3AK cells and their therapeutic effect against malignant tumor
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the clinical quality control of PHA-CD3AK cells induced by PHA, anti-CD3 monoclonal antibody and rhIL-2, and their therapeutic effects against malignant tumors. Methods: Fifty-three patients with advanced malignant tumor were from Friendship Hospital of Shaanxi Province. Peripheral blood mononuclear cells (PBMC) were obtained and induced to differentiate into autologous PHA-CD3AK cells by PHA, anti-CD3mAb and rhIL-2. Quality control indices including quantity, viability, cytotoxicity, endotoxin contaminant and infection source of PHA-CD3AK cells were examined, and the immunophenotypes were studied by flow cytometry. The qualified autologous PHA-CD3AK cells were gathered and infused back to the tumor patients intravenously, once every 2 days; each episode included 6 times, with a total of 2 courses. Therapeutic effects and adverse reactions were observed, and the effective and clinical beneficial rates were calculated. Results: The prepared PHA-CD3AK cells met the quality standard of the expected immune activated cells. The ratios of CD3+T, CD4+T, CD8+T and CD16+ CD56+ cells in the peripheral blood were (49.36±9.21)%, (34.85±4.35)%, (29.20±5.12)% and (21.15±6.50)% respectively after treatment with autologous PHA-CD3AK cells, which were significantly higher than those before treatment (all P<0.05). The general symptoms of most patients were obviously improved (43/53), with 6 cases reaching CR, 14 cases reaching PR, 10 cases reaching MR, 14 cases reaching SD, 9 cases reaching progression; the total effective rate was 56.6%, and the clinical beneficial rate was 83.0%. There were no abnormal changes of the related chemical indices or toxicity reaction. Conclusion: Our quality control method for prepared PHA-CD3AK cells is feasible, and they have definite therapeutic effects against malignant tumor and can efficiently improve the immune function of tumor patients.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of Shaanxi Province (No. 2007C260)
Clc Number:
